Greenland Technologies Holding Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Greenland Technologies Holding Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.69M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $83.94M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $90.33M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $90.83M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $98.84M | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $66.86M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $52.40M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $60.21M | Apr 3, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.45M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $22.53M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $24.58M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $19.83M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $19.59M | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $12.81M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $12.38M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $14.07M | Apr 3, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.93M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $14.07M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($15.88M) | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $745.6K | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $6.27M | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $6.76M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.46M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.62M | Apr 3, 2020 |
| FY2018 | Nov 30, 2018 | ($66.8K) | Feb 27, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.52M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $12.59M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $10.78M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $5.96M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $8.25M | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $6.71M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.60M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $8.70M | Apr 3, 2020 |
| FY2018 | Nov 30, 2018 | ($373.0K) | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.92M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $2.94M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $5.42M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $5.79M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $5.53M | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $2.38M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.36M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.51M | Apr 3, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.61M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $13.34M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $2.45M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $7.31M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | ($5.76M) | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $2.70M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $8.00M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.06M | Apr 3, 2020 |
| FY2018 | Nov 30, 2018 | ($426.3K) | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $525.7K | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $1.96M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $735.5K | Mar 26, 2025 |
| FY2019 | Dec 31, 2019 | $1.28M | Apr 3, 2020 |
| FY2019 | Dec 31, 2018 | $6.69M | Apr 3, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.77M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $115.58M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $130.48M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $155.12M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $162.57M | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $131.98M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $106.48M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $111.41M | Apr 3, 2020 |
| FY2018 | Nov 30, 2018 | $45.04M | Feb 27, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.45M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $62.31M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $79.82M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $75.68M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $87.72M | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $81.32M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $59.52M | Mar 31, 2021 |
| FY2018 | Nov 30, 2018 | $1.01M | Feb 27, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.94M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $60.21M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $50.08M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $65.71M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $62.28M | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $44.89M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $38.60M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $31.74M | Apr 3, 2020 |
| FY2018 | Nov 30, 2018 | $5.00M | Feb 27, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $3.9K | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $3.9K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.9K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.0K | Apr 3, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.53M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $32.60M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $18.54M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $34.41M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $33.67M | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $26.73M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $19.86M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $15.93M | Apr 3, 2020 |
| FY2018 | Nov 30, 2018 | ($66.8K) | Feb 27, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.78M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $6.66M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $22.98M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $16.30M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $11.06M | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $7.16M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.12M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.56M | Apr 3, 2020 |
| FY2018 | Nov 30, 2018 | $644.7K | Feb 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $197.9K | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | $963.5K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.00M | Mar 31, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 17.39M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 13.59M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 13.59M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | 12.98M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | 11.33M | Apr 17, 2024 |
| FY2021 | Dec 31, 2020 | 10.23M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 10.01M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 7.50M | Apr 3, 2020 |
| FY2018 | Nov 30, 2018 | 1.91M | Feb 27, 2019 |